Compare JANX & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JANX | OMER |
|---|---|---|
| Founded | 2017 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 2021 | 2008 |
| Metric | JANX | OMER |
|---|---|---|
| Price | $10.13 | $13.29 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 3 |
| Target Price | ★ $33.14 | $27.50 |
| AVG Volume (30 Days) | 946.4K | ★ 1.2M |
| Earning Date | 11-05-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 98.15 |
| EPS | N/A | ★ 0.13 |
| Revenue | $10,000,000.00 | ★ $29,868,000.00 |
| Revenue This Year | $174.21 | N/A |
| Revenue Next Year | N/A | $66.13 |
| P/E Ratio | ★ N/A | $107.77 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.16 | $6.70 |
| 52 Week High | $35.34 | $21.24 |
| Indicator | JANX | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 25.34 | 30.78 |
| Support Level | N/A | $9.45 |
| Resistance Level | $14.47 | $19.68 |
| Average True Range (ATR) | 1.16 | 0.92 |
| MACD | -0.48 | -0.45 |
| Stochastic Oscillator | 0.33 | 8.90 |
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.